<DOC>
	<DOCNO>NCT02359526</DOCNO>
	<brief_summary>To provide treat physician experience ILUVIEN well monitor safety ( effectiveness ) real-life chronic diabetic macular edema ( DME ) patient judge insufficiently responsive available therapy .</brief_summary>
	<brief_title>A Pilot Study Effect Safety Iluvien® Chronic Diabetic Macular Edema Patients</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Fluocinolone Acetonide</mesh_term>
	<criteria>Chronic DME patient consider insufficiently responsive available therapy ( laser , antiVEGF ) without intravitreal corticosteroid therapy . Adults ( ≥18 year ) chronic DME ; Patients consider insufficiently responsive define underwent previous treatment , include least 3 antiVEGF injection last 6 month , follow : 1 . Mean central foveal thickness ( central subfield thickness ) ≥ 290 um woman ≥ 305 um men Zeiss Cirrus OR ≥ 305 um woman ≥ 320 um men Heidelberg Spectralis , study eye measure use SDOCT ; 2 . Vision impairment ( 20/50 20/400 use Snellen visual acuity equivalent ) relate DME ; 3 . If Investigator 's opinion improvement possible . IOP &gt; 21 mmHg screening ( day 14 ) study eye . Historical rise IOP &gt; 25 mmHg follow treatment intravitreal corticosteroid study eye . Use ≥ 2 active agent IOPlowering medication control IOP screening study eye . Vitreomacular traction DME opaque medium study eye . Severe proliferative diabetic retinopathy require pan retinal photocoagulation study eye . Pregnant breastfeed woman . Active angiographic central macular ischaemia baseline study eye . Pan retinal photocoagulation cataract surgery 3 month baseline study eye . Presence preexist glaucoma , active suspect ocular periocular infection and/or hypersensitive active agent one excipients . Women childbearing potential , defined woman physiologically capable become pregnant UNLESS : use highly effective method birth control .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Chronic Diabetic Macular Edema</keyword>
	<keyword>Iluvien</keyword>
	<keyword>Intra-vitreal injection</keyword>
	<keyword>Pilot study</keyword>
</DOC>